Set-in-stone criteria will reduce risk for new biotech fund
Several boxes must be ticked off before new Danish-Swedish biotech fund Sound Bioventures is ready to invest. A high-energy team, the right development stage and an indication on the smaller side are all on the list, but medtech and diagnostic firms have been excluded, says founding partner Casper Breum.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
For many years, promising Danish life science firms and imaginative biotech entrepreneurs only had a few funds to turn to when raising capital to secure their futures: Lundbeckfonden, the Novo Nordisk Foundation and Sunstone Life Science Ventures.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.